News

A landmark study led by Monash University has revealed a sharp rise in endometriosis diagnoses among women attending Australian general practices over the past decade. The researchers say the...

Heather Cahill, Oncology Business Director for AstraZeneca Australia and New Zealand, says healthy women are integral to thriving societies. Yet globally, breast cancer remains the leading cause of female cancer deaths. She highlights the launch of the Breast Cancer Care Quality Index and urges action to turn ambitious global targets into measurable outcomes.

Public confidence in Australia’s healthcare system may be showing subtle cracks, with new global data revealing both a softening in vaccination support and growing concern over access to treatment, even as overall ratings of care remain comparatively high.

Pharmac has announced a proposal to clarify how long lower-priority medicine applications can remain on its Options for Investment list before being formally declined.

“This work has the potential to transform the way we respond to some of the most pressing health challenges,” said Professor Robyn Ward, Monash Deputy Vice-Chancellor (Research and Enterprise). “Just a few years ago, this was an ambitious idea in a lab. Now, it could help drive the next generation of therapies.”

Radiopharm Theranostics (ASX:RAD) unveiled promising clinical data across multiple radiopharmaceutical programs while securing A$40 million in new funding to accelerate its growing oncology pipeline.

Managing Director for Australia and New Zealand Alice Tien said the result underscored Biogen’s commitment to creating a workplace where inclusion and collaboration are prioritised.

Algorae Pharmaceuticals (ASX:1AI) has announced a major strategic partnership with Cadila Pharmaceuticals, one of India’s largest privately held pharmaceutical companies, marking a significant step in the Australian company’s commercial expansion across key therapeutic markets.

Orthocell (ASX:OCC) has deepened its investment in Western Australian biotech innovator Marine Biomedical, securing global distribution rights to an innovative bone regeneration technology as part of a strategic expansion of its regenerative medicine portfolio.

Immutep (ASX:IMM) has unveiled a pair of significant clinical developments that underscore its ambition to reshape cancer treatment, announcing positive results in both soft tissue sarcoma and first-line non-small cell lung cancer at the 2025 European Society for Medical Oncology Congress in Berlin.

Many New Zealanders living with chronic health conditions will soon find it easier to access essential medicines and health consumables, following a significant decision by Pharmac to cut administrative red tape.